21 hours ago
7
You have a preview view of this article while we are checking your access. When we have confirmed access, the full article content will load.
Trump cutbacks were supposedly aimed at administrators. But scientists in food and drug-testing labs and policy experts who advance generic drug approvals were also dismissed.
April 3, 2025, 3:00 p.m. ET
Health Secretary Robert F. Kennedy Jr. announced wide-ranging cutbacks at federal health agencies, including the Food and Drug Administration, that would eliminate duplicative services and paper pushers.
But in interviews with more than a dozen current and former F.D.A. staff members, a different picture emerged of the far-reaching effects of the layoffs that would ultimately reduce the agency work force by 20 percent. Among them are experts who navigated a maze of laws to determine if an expensive drug can be sold as a low-cost generic; lab scientists who tested food and drugs for contaminants or deadly bacteria; veterinary division specialists investigating bird flu transmission; and researchers who monitored televised ads for false claims about prescription drugs.
In many areas of the F.D.A., no employees remain to process payroll, to file retirement or layoff paperwork and to help overseas inspectors who are at risk of maxing out agency credit cards. Even the agency’s library, where researchers and experts relied on medical journal subscriptions that have now been canceled, has been shut down.
The F.D.A.’s new commissioner, Dr. Marty Makary, showed up for a long-awaited appearance at the agency’s Maryland headquarters on Wednesday. He delivered a speech outlining broad problems in the health care system, including a rise in chronic diseases. Employees were not given a formal opportunity to ask questions.
About 3,500 F.D.A. employees are expected to lose their jobs under the reductions. A spokesman for Health and Human Services did not respond to questions.
When the Trump administration executed its first round of cuts to the F.D.A. in February, it gutted teams of scientists who did the delicate work of ensuring the safety of surgical robots and devices that infuse insulin in children with diabetes. Some of the layoffs and cutbacks, described by former F.D.A. officials as arbitrary, were rapidly reversed.
